A Double-Blind, Placebo- and Positive-Controlled, Randomized, Partial 6-way Crossover Study to Investigate the Pharmacodynamics and Pharmacokinetics of CEP-26401 (5, 25, and 125 microg) Following Single-Dose Administration to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2019
Price : $35 *
At a glance
- Drugs Irdabisant (Primary) ; Donepezil; Modafinil
- Indications Cognition disorders
- Focus Pharmacodynamics
- Sponsors Teva Pharmaceutical Industries
- 02 Feb 2019 Results published in the British Journal of Clinical Pharmacology
- 02 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 18 Oct 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.